Trial reportSurgical endoscopy2009
Improvement in glycemic control by gastric electrical stimulation (TANTALUS) in overweight subjects with type 2 diabetes.
Trial report in Surgical endoscopy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Systematic review on gastric electrical stimulation in obesity treatment.Expert review of medical devices · 2019Pooled it
- Gastric electrical stimulation with the TANTALUS System in obese type 2 diabetes patients: effect on weight and glycemic control.Journal of diabetes science and technology · 2009Trial
- Duodenal myoelectrical hyperactivity drives diabetic remission in rat models of type 2 diabetes.Diabetologia · 2026Article
- Review
- Use of Bioelectronics in the Gastrointestinal Tract.Cold Spring Harbor perspectives in medicine · 2019Review
- Ghrelin, CCK, GLP-1, and PYY(3-36): Secretory Controls and Physiological Roles in Eating and Glycemia in Health, Obesity, and After RYGB.Physiological reviews · 2017Review
- A pilot study to compare meal-triggered gastric electrical stimulation and insulin treatment in Chinese obese type 2 diabetes.Diabetes technology & therapeutics · 2015Article
- Neurostimulation of the gastrointestinal tract: review of recent developments.Neuromodulation : journal of the International Neuromodulation Society · 2015Review
- The DIAMOND system in the treatment of type 2 diabetes mellitus in an obese patient.Wideochirurgia i inne techniki maloinwazyjne = Videosurgery and other miniinvasive techniques · 2014Article
- Updates on gastric electrical stimulation to treat obesity: Systematic review and future perspectives.World journal of gastrointestinal endoscopy · 2014Article
- Parameter selection and stimulating effects of an adjustable gastric electrical stimulator in dogs.Obesity surgery · 2014Article
- Fasting plasma triglycerides predict the glycaemic response to treatment of type 2 diabetes by gastric electrical stimulation. A novel lipotoxicity paradigm.Diabetic medicine : a journal of the British Diabetic Association · 2013Article
- Gastric stimulation for weight loss.World journal of gastroenterology · 2012Review
- Diabetic and bariatric surgery: a review of the recent trends.Surgical endoscopy · 2012Review
- Micro-orifice metabolic/bariatric surgery under IV sedation/local anesthesia: porcine feasibility study.Obesity surgery · 2010Article
- Vagal nerve function in obesity: therapeutic implications.World journal of surgery · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe TANTALUS system (MetaCure Ltd.) is a minimally invasive implantable gastric stimulation modality that does not exhibit malabsorptive or restrictive characteristics. The device applies gastric contractility modulation (GCM) signals to the stomach antrum. The signals are delivered in synchronization to the native electrical activity of the stomach during meals. Retrospective analysis of previous studies indicated that type 2 diabetes mellitus (T2DM) subjects on oral medication with hemoglobin A1c (HbA1c) between 7.5% and 9.5% are the population with most potential benefit from the treatment. The current study includes subjects enrolled prospectively within that range of HbA1c.
aimTo prospectively investigate the potential effect of the TANTALUS system on glycemic control and weight in overweight subjects with T2DM.
methodsIn this European multicenter, open-label study, 13 T2DM obese (6 male, 7 female, BMI 37.2 +/- 1.0 kg/m(2), range 30.4-44.0 kg/m(2)) subjects treated with oral antidiabetic medications but with poor glycemic control (HbA1c > or = 7%, range 7.3-9.5%) were implanted laparoscopically with the TANTALUS system.
resultsThirteen subjects that had completed 3 months of treatment showed a significant reduction in HbA1c from 8.0 +/- 0.2% to 6.9 +/- 0.1% (p < 0.05), whereas fasting blood glucose decreased from 175 +/- 6 mg/dL to 127 +/- 8 mg/dL (p < 0.05). The glycemic improvement was accompanied by reduction in weight from 104.4 +/- 4.4 kg to 99.7 +/- 4.8 kg, and in waist circumference from 122.3 +/- 3.2 cm to 117.0 +/- 3.0 cm.
conclusionsInterim results with the TANTALUS system suggest that this stimulation regime can potentially improve glucose levels and induce moderate weight loss in obese T2DM subjects on oral antidiabetic therapy with poor glycemic control. Further evaluation is required to determine whether this effect is due to induced weight loss and/or due to direct signal-dependent mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.